drugset / Trial / NCT06354127

DWP450 for Treating Moderate to Severe Glabellar Lines

NCT06354127

Phase 3 Completed 473 enrolled Daewoong Pharmaceutical Co. LTD.
RandomizedParallel-groupDouble-blindTreatment

Summary

A multi-center, randomized, double-blind, positive drug-controlled clinical study to evaluate the safety and efficacy of Botulinum Toxin Type A for Injection in the treatment of moderate to severe glabellar lines

Timeline

Start
2020-08-12
Primary completion
2020-11-24
Completion
2021-01-25

Drugs

EvaluationDrugModalityDoseRoute
Comparator Botulinum toxin type A Protein / enzyme biologic Other
Subject PrabotulinumtoxinA Protein / enzyme biologic Other

Indications

No indication recorded.